Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Anti-Inflammatory pill may rewire food choices in overweight people

NCT ID NCT05785429

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether colchicine, a common anti-inflammatory drug, can change how the brain values effort and reward when making food choices. 59 overweight women with mild inflammation took either colchicine or a placebo daily for 12 weeks. Researchers used brain scans and behavior tests to see if the drug made them more willing to work for healthier, lower-calorie foods.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
colchicine
What this could lead to
If it works, this could point toward a treatment that helps people with overweight make healthier food choices by reducing inflammation.
What could go wrong
This is a small, early-stage study (59 people) that only looked at brain activity and behavior, not weight loss. Results may not apply to everyone, and colchicine can cause side effects like stomach upset.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

59 people

The number who actually took part.

Started

Aug 2022

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 59 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI ≥ 27 kg/m2 * Female sex * Right-handed * Age: 18-59 years * Shoulder width of \< 68 cm (to fit into the MRI scanner) * Dutch speaking - Sufficient level to understand task instructions * Low-grade inflammatory state, as measured by C-reactive protein (CRP) between 3.0 and 10.0 mg/L Exclusion Criteria: * Having been vaccinated by any type of vaccine in the 4 weeks preceding the first test session * Having had an infection characterized by a fever, or diagnosed by a medical physician in the 4 weeks preceding the first test session * Diagnosed with Diabetes Mellitus type I or II * Gained or lost \>2 points in BMI (kg/m2) over the last 6 months * Followed an energy restricting diet during the last 2 months * Having had bariatric surgery in the past 5 years * Regular use of anti-inflammatory, anti-diabetic, weight-loss, and psychoactive medication * Regular use of CYP3A4 inhibitors, P-glycoprotein inhibitors, statins, fibrates, ciclosporin, and digoxin, as a contraindication for colchicine * Have renal impairment as evidenced by serum creatinine \>150 μmol/l or eGFR \<50mL/min/1.73m2, determined maximum 12 weeks before inclusion * Have moderate to severe hepatic disease * (History of) clinically significant psychiatric or neurological disorder * (History of) clinically significant metabolic, cardiovascular, renal, liver, endocrinological, autoimmune or chronic inflammatory disease * General medical conditions, such as sensorimotor handicaps, deafness, blindness or colour-blindness, as judged by the investigator * Current or history of alcohol and/or drugs abuse (i.e. \>14 units per week) * Habitual smoking, i.e. one or more cigarettes per day * Pregnant, lactating or wishing to become pregnant in the period between the screening and until 3 months after the last study visit * Participation in another weight loss, lifestyle or anti-inflammatory intervention in the context of research at the time of inclusion or during the study * Contraindications for MRI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overweight and obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Inflammation Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Donders Centre for Cognitive Neuroimaging

    Nijmegen, 9525EN, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.